Spironolactone effect on cardiac structure and function of patients with heart failure and preserved ejection fraction: a pooled analysis of three randomized trials.

Fiche publication


Date publication

octobre 2022

Journal

European journal of heart failure

Auteurs

Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick


Tous les auteurs :
Ferreira JP, Cleland JG, Girerd N, Bozec E, Rossignol P, Pellicori P, Cosmi F, Mariottoni B, Solomon SD, Pitt B, Pfeffer MA, Shah AM, Petutschnigg J, Pieske B, Edelmann F, Zannad F

Résumé

Spironolactone is currently used in a large proportion of patients with heart failure and preserved ejection fraction (HFpEF), yet its effects on cardiac structure and function in a large population has not been well established.

Mots clés

HFpEF, cardiac structure and function, echocardiography, spironolactone, treatment effect

Référence

Eur J Heart Fail. 2022 10 27;: